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FractureAims: Mixed evidence exists for the effect of incretin-based therapies on osteoporosis in
type-2 diabetes. Therefore, we conducted a cohort study to determine the association
between dipeptidyl peptidase-4 (DPP-4) inhibitors and common osteoporotic ‘‘fragility frac-
tures” (upper extremity, hip, spine).
Methods: The UK-based Clinical Practice Research Datalink was used to identify adults
without prior fractures receiving a new anti-diabetic drug or a new type-2 diabetes diagno-
sis between 2007 and 2016. The primary aim was to compare new-users of DPP-4 inhibitors
versus new-users of sulfonylureas (SU). The association between DPP-4 inhibitors and inci-
dent fractures was estimated using Cox proportional hazards models. Deciles of high-
dimensional propensity scores and other anti-diabetic drugs were used as covariates.
Results: We identified 7993 and 26,636 new-users of DPP-4 inhibitors and SUs, respectively.
At cohort entry, the mean age was 58.8, 40% were female, mean diabetes duration was 1.3
years, and 42% had A1c > 9%. Over 9 years (mean follow-up = 1.2 years), the incident rate of
fragility fractures was lower among DPP-4 versus SU users (3.0/1000 vs. 5.2/1000 person-
years; P-value = 0.007). After adjustment, there was no statistically significant difference
in fracture risk (hazard ratio adjusted, aHR = 0.80, 95%CI 0.51–1.24; P-value = 0.3125). In a
secondary analysis, DPP-4 inhibitors were not associated with a difference in fracture risk
compared to insulin (aHR = 0.91, 95%CI 0.40–2.09); however were associated with a lower
fracture risk versus thiazolidinediones (aHR = 0.47, 95%CI 0.26–0.83). Sensitivity analyses
supported findings.
Conclusions: DPP-4 inhibitors are not associated with an increased risk of fragility fractures
compared with SUs or insulin; however, are associated with a lower risk versus
thiazolidinediones.
 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Canada.
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Patients with type 2 diabetes have increased bone mineral
density and yet have a very high risk of osteoporotic fractures
due to a clustering of risk factors such as postmenopausal
status, smoking, advanced age, low physical activity,
increased falls related to visual impairment and neuropathy,
and increased frailty [1]. Studies have consistently demon-
strated that having type 2 diabetes increases the risk of fragi-
lity fractures or major osteoporotic fractures (MOF), terms
that collectively refer to low-trauma fractures of the hip,
spine, distal radium, and proximal humerus [2–4]. The risk
is estimated to be increased by 20–30% for all MOF together,
with an increase as high as 70–80% for hip fractures specifi-
cally [5].
In 2006, the ADOPT trial [6] demonstrated that rosiglita-
zone had twice the risk of fractures compared to both met-
formin and glyburide in women with no difference observed
in men. These results were duplicated with rosiglitazone with
a re-analysis of the PROactive trial, showing the same two-
fold increase in fracture risk among women [7]. Subsequent
studies have uncovered possible mechanisms responsible
for increasing the risk of fractures, and assessed fracture risk
associated with other anti-diabetic drugs. The thiazolidine-
dione class effect is theorized to result from adipocyte differ-
entiation resulting from PPAR-g activation [8], and they
induce bone marrow stromal cells toward adipocyte differen-
tiation over osteoblastic differentiation. Observational studies
have shown insulin increases fracture risks [9,10] despite
known positive effects of insulin in bone matrix synthesis
[11]. This increase may be the result of a higher risk of hypo-
glycemia leading to a greater number of falls and fractures.
Other longstanding anti-diabetic drugs such as metformin,
meglitinides, a-glucosidase inhibitors and sulfonylureas are
believed to have neutral impacts on bone metabolism [12].
Clinical trials of newer agents, including the dipeptidyl-
peptidase-4 (DPP-4) inhibitors, have reported on the risk of
fracture, however long-term safety data is limited. An early
meta-analysis of phase 2 and 3 DPP-4 inhibitor trials found
a 40% reduction in fracture risk, purportedly attributed to
the increased bone mineral density [13]. Only 63 fracture
events were reported and long-term follow-up was limited.
However, more recent meta-analyses have found no differ-
ences in fracture risk among DPP-4 inhibitor users compared
to placebo or active comparators [14,15]. Similarly, observa-
tional data examining the association between DPP-4 inhibi-
tors and fragility fractures does not support either an
increased or decreased fracture risk [16–20]. Substantial vari-
ation exists in the study design, power, and analysis of previ-
ous observational studies.
Despite increased reporting of fracture as an outcome in
diabetes therapy clinical trials, there still remains a paucity
of evidence of the true long-term risk of DPP-4 inhibitor ther-
apies on the occurrence of fragility fractures in the diabetes
population compared to other classes of diabetes therapies.
The aim of this study was to estimate the risk of fragility frac-
tures after exposure to DPP-4 inhibitor initiators compared to
sulfonylurea initiators and other anti-diabetic drugs.2. Subjects, materials and methods
2.1. Study design and data sources
We used a cohort design to evaluate the comparative safety of
DPP-4 inhibitors with respect to fragility fractures using the
Clinical Practice Research Datalink (CPRD) database. The
dataset includes longitudinal de-identified electronic medical
data from primary care visits with general practitioners. It has
records from more than 650 practices across the United King-
dom, representing approximately 7% of the UK population
and is representative of the broader population [21]. The
available information includes patient sociodemographic
data (e.g., health behaviors, smoking status), physiological
measures (e.g. blood pressure), laboratory data (e.g. glycated
hemoglobin [HbA1c]), clinician-assigned diagnoses (via READ
codes), and outpatient prescription records. Data from the
CPRD include only patients acceptable for research based on
numerous data quality checks [21].
Individuals were included in the source population if they
met each of the following criteria between January 1st, 2001
and the end of the CPRD GOLD dataset for the study period
(February 2016): (1) received a new prescription for any anti-
diabetic agent or had a new diagnostic record for type 2 dia-
betes, with no previous anti-diabetic prescription or diagnos-
tic record within the previous 365 days (The study entry date
was defined as the first of a new anti-diabetic prescription or
type 2 diabetes diagnosis); (2) had a minimum of 12 months of
up-to-standard medical history prior to their study entry date;
and (3) were at least 18 years of age at the time of their study
entry date. In addition, we linked a subset of our source pop-
ulation (58%) to hospitalization records, death certificate,
and socioeconomic status information from the Hospital Epi-
sode Statistics (HES – data available up to March 31, 2014), the
Office of National Statistics (ONS – data available up to April
30, 2014), and index of multiple deprivation (2010) databases,
respectively. We excluded women with polycystic ovarian
syndrome, pregnant women, and those with gestational dia-
betes. In addition, to minimize selection bias we excluded
patients with a history of an osteoporotic or fragility fracture,
osteoporosis, osteomalacia, neoplasms (non-skin), or who
received a prescription for a bisphosphonate, calcitonin,
denosumab, raloxifene or tereparatide within a year prior to
their cohort entry date.
Our study protocol was approved by the Independent Sci-
entific Advisory Committee (ISAC 15_016RARA, August 2017)
and the Health Research Ethics Board at Memorial University.
2.2. Exposure
Exposure status was defined as new use of one of the follow-
ing medication classes: (1) DPP-4 inhibitors, (2) Glucagon-like
peptide-1 (GLP-1) receptor agonists, (3) Metformin, (4) Sul-
fonylureas, (5) Thiazolidinediones, (6) Sodium glucose co-
transporter-2 (SGLT2) inhibitors, (7) Meglinides, (8) Acarbose,
(9) Insulin. Periods of no anti-diabetic medication exposure
were defined as diet/lifestyle management (no therapy). Indi-
viduals contributed person-time into the exposure categories
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 3 6 ( 2 0 1 8 ) 1 5 9 –1 6 7 161of interest beginning on the first day a patient was prescribed
a new anti-diabetic drug or newly diagnosed with diabetes
after January 1, 2007, which was set as the index date. Individ-
uals were censored once they discontinued the medication,
began therapy with a comparator medication, left the CPRD
participating practice, died or on the last day of documented
follow-up, whichever occurred first. To account for potential
non-adherence, whenever a no treatment gap of less than
1.5 times of the average day supply (45 days) was observed,
we replaced this gap with the previous therapy. Similarly,
whenever a therapy gap of less than the average day supply
(30 days) was observed, we replaced this therapy gap with
the previous therapy. Where there were overlaps of less than
30 days between anti-diabetic medications, we censored the
discontinued medication at the time of the medication start
for the medication being initiated. Where medication dura-
tion was unable to be calculated, a 30-day duration was
assumed.
2.3. Outcomes
Our primary endpoint was time to the first diagnosis of fragi-
lity fracture recorded during the study follow-up period in the
CPRD GOLD database or HES database. Fragility fracture was
defined based on READ codes contained in the GOLD data
and ICD-10 codes in the HES data (see Supplementary Appen-
dix Table S1 for list of codes). Our secondary outcomes were
based on fracture location including the hip, spine, distal
radium, and proximal humerus.
2.4. Covariates
We used high-dimensional propensity scores (hdPS) to adjust
for potential confounding whereby we selected 40 covariates
from hundreds of potential confounders through an empiri-
cal, multi-step process [22]. Logistic regression was used to
estimate the propensity score or predicted probability of
exposure to DPP-4 inhibitors compared to sulfonylureas (or
other comparators in sensitivity analyses), conditional on
the 40 empirical variables identified from the hdPS procedure
and several pre-defined covariates measured within the 365
days prior to the index date. Pre-defined covariates (Supple-
mentary Appendix Table S2) included age, sex, smoking sta-
tus, socioeconomic status, year of cohort entry, alcohol
abuse, body mass index, duration of diabetes, history of cir-
rhosis, heart failure, hypertension, hyperlipidemia, ischemic
heart disease, peripheral vascular disease, number of hospi-
talizations, number of distinct prescription drugs, most
recent HbA1c value, prescription for a bisphosphonate, estro-
gen, oral contraceptive, oral corticosteroid, thiazide diuretics,
and anti-diabetic agents prior to initiating a DPP-4 inhibitor or
comparator agent. Patients without overlapping propensity
scores were trimmed from analyses.
2.5. Statistical analysis
Standard descriptive statistics were used to compare the
characteristics of DPP-4 inhibitor users with sulfonylurea
users. Although no ideal active comparator exists, our pri-mary analysis pre-specified sulfonylurea users as an active
comparator referent group because sulfonylureas represents
the largest comparison group and they are used in a similar
clinical framework (i.e., often used as second and third line
agents following metformin monotherapy) as DPP-4 inhibi-
tors. Patients contributed time at risk for either a DPP-4 inhi-
bitor or a sulfonylurea until the first gap in therapy, or a
switch from a DPP-4 inhibitor to a sulfonylurea, or switch
from a sulfonylurea to a DPP-4 inhibitor. Therefore, once a
patient has initiated a DPP-4 inhibitor or sulfonylurea, they
were continuously exposed until experiencing an event or
censored. Multivariable Cox Proportional Hazards regression
analysis was used to estimate the independent association
between DPP-4 inhibitor use and the risk of fragility fractures
after controlling for multiple potential confounders. Covari-
ates included deciles of the high-dimensional propensity
scores, as well as an ordinal time-dependent variable indicat-
ing the number of anti-diabetic agents an individual was
exposed to during follow-up (1, 2, or 3+). We used standard
Cox proportional hazards regression methods to estimate an
unadjusted and adjusted hazard ratio and 95% confidence
interval (2-sided p-values) and to check for model assump-
tions. Assuming 25% of the cohort is exposed to a DPP-4 inhi-
bitor and a fracture rate of 2% [16,19], approximately 33,628
patients are required to detect a 20% relative risk reduction
(i.e. hazard ratio of 0.80).
For the secondary analysis, the reference group was varied
to examine the difference between DPP-4 inhibitors and other
anti-diabetic medication classes. For each exposure contrast
(e.g. DPP-4 inhibitors vs. thiazolidinediones and DPP-4 inhibi-
tors vs. insulin) a new analytic cohort was identified whereby
the high-dimensional propensity score procedure was rerun
and trimming was applied to form new analytic cohorts for
each comparison of interest.
In addition to our primary and secondary analyses, we also
conducted a number of sensitivity analyses, including:
1. Repeating the main analysis using a matched propensity
score to control for confounding. Patients were matched
1:1 using a greedy nearest neighbor approach with treated
patients selected in random order.
2. Repeating the main analysis restricting the cohort to
patients eligible for HES linkage.
3. Repeating our main analysis using alternative methods to
define our drug exposure over time. First, we restricted the
population to monotherapy users. Second, we restricted
the population to patients initiating metformin monother-
apy who added-on a DPP-4 inhibitor or sulfonylurea. Third,
we used time-dependent variables to classify person-time
over a patient’s entire follow-up period based to further
explore DPP-4 inhibitor monotherapy vs. sulfonylurea
monotherapy, DPP-4 inhibitor monotherapy vs. metformin
monotherapy, and DPP-4 inhibitor combination therapy
(DPP-4 inhibitor/metformin, DPP-4 inhibitor/SU, and DPP-
4 inhibitor/insulin, vs. metformin/SU [referent category]).
4. Conducting an additional analysis whereby patients
exposed to a DPP-4 inhibitor were grouped with patients
exposed to a sulfonylurea who had identical ordering of
exposure to other anti-diabetic medication classes. In
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fonylurea users, we grouped patients who were exposed
to identical anti-diabetic regimens with the exception of
DPP-4 inhibitors and sulfonylureas. For example, when
comparing initiators of DPP-4 inhibitors vs. sulfonylurea,
patients who started with metformin as the first line ther-
apy and then added DPP-4 inhibitor are in the same group
as the subjects who started with metformin and added
sulfonylurea. We removed from the analysis patients
who are in groups with less than 25 people. This approach
reduces the power of the analysis (compared to our pri-
mary analysis); however, patients using the most frequent
and clinically relevant anti-diabetic regimens are included
in the analysis. We adjusted for groups by using a categor-
ical variable with K groups within our multivariable cox
proportional hazards model, whereby K is the total num-
ber of groups. Deciles of the propensity score were also
included as covariates in our model to be consistent with
the main analysis.
5. Repeating the primary analysis on our secondary out-
comes (i.e. location of fracture: hip, spine, distal radium,
and proximal humerus).
All analyses were conducted with R version 3.3.3.
3. Results
A total of 130,236 patients from within the CPRD dataset met
our inclusion criteria (Fig. 1). There were 7993 and 26,636 new
users of DPP-4 inhibitors and sulfonylureas respectively; of
these 4273 (53%) and 15,510 (58%) were linked to HES and
ONS data. Mean duration of follow-up was 1.2 years, with a
maximum follow-up of 9 years. Patients initiating DPP-4 inhi-
bitors were on average younger, had a longer history with
type 2 diabetes, less likely to have prior hospitalizations,
had a lower HbA1c, and less likely to have impaired renal
function (Table 1). However, a comparison of groups after
matching with the high-density propensity score showed
similarities across patient characteristics including prior
antidiabetic use (Supplementary Appendix Table S3).
After 40,203 years of person-time follow-up there were a
total of 189 fractures among new users of DPP-4 inhibitors
(n = 27, incidence rate = 3.0 per 1000 person-years) and sul-
fonylureas (n = 162, incidence rate = 5.2 per 1000 person-
years) (Table 2A). Though the crude hazard ratio (HR 0.57,
95% CI 0.38–0.86) suggested a significant lower risk of frac-
tures among DPP-4 initiators compared to sulfonylurea initia-
tors, the association dissipated after adjustment for
confounding (adjusted HR (aHR) 0.80, 95% CI 0.51–1.24). Simi-
larly, we did not observe an association between DPP-4 inhibi-
tor initiation and fractures when compared to insulin (aHR =
0.91, 95% CI 0.40–2.09) (Table 2B). Of note, however, DPP-4
inhibitors were associated with a significantly lower fracture
risk when compared with thiazolidinediones (aHR = 0.47,
95% CI 0.26–0.83) (Table 2C).
Fig. 2 presents the summary of the sensitivity analysis
comparing DPP-4 inhibitors against SU (detailed results are
reported in supplementary Tables S4-S9) based on: (1)
matched propensity scores (HR 0.90, 95% CI 0.53–1.53)(Table S4); (2) restriction to HES linked data only (HR 0.88,
95% CI 0.49–1.56) (Table S5); (3) adjusted for anti-diabetic ther-
apy pattern (HR 0.72, 95% CI 0.42–1.23) (Table S6); (4) restric-
tion to individuals on monotherapy (HR 0.28, 95% CI 0.04–
2.20) (Table S7); (5) restriction to patients who combined met-
formin with a DPP-4 inhibitor or sulfonylurea as a second-line
add on therapy (HR 0.82, 95% CI 0.34–1.99) (Table S8); (6) time-
dependent DPP-4 inhibitor monotherapy vs. sulfonylurea
monotherapy (HR 0.73, 95% CI 0.42–1.27), DPP-4 inhibitor
monotherapy vs. metformin monotherapy (HR 0.88, 95% CI
0.52–1.50), and DPP-4 inihibitor combination therapy use
(DPP4i/metformin vs. SU/metformin: HR 0.67, 95% CI 0.41–
1.10; DPP4i/SU vs. SU/metformin: HR 0.98, 95% CI 0.48–2.03)
(Tables S9a, S9b, Sdc) and (7) a break down based on fracture
location (wrist, humerus, vertebral and hip) (Tables S10-S13).
The results from the sensitivity analysis were consistent with
the primary analysis, showing no statistically significant
differences.
4. Discussion
In this large representative cohort of type 2 diabetes patients
in the UK, we found that the incidence of fragility fracture
was 4.7 per 1000 patient years. Following adjustment for
potential confounding, there was no statistically significant
association between DPP-4 inhibitor use and the risk of frac-
tures compared to sulfonylurea use. Numerous sensitivity
analyses demonstrated consistent findings, with the excep-
tion of thiazolidinediones which were associated with an
increased risk of fragility fractures compared to DPP-4
inhibitors.
Our study provides some important clinical and statistical
insights into the risk profile of DPP-4 inhibitors that helps bet-
ter explain both previous meta-analyses of RCTs [14,15] and
observational studies [16–20]. Previous meta-analyses identi-
fied RCTs that compared DPP-4 inhibitors to either placebo
or an active anti-diabetic therapy. Mamza et al. (2016)
included 51 eligible studies (N = 36,402) and found no signifi-
cant difference in fracture risk between DPP-4 and placebo
(37 studies, OR; 0.82, 95% CI 0.57–1.16, P = 0.9) or active com-
parator (14 studies, OR; 1.59, 95% CI 0.91–2.80, P = 0.9). Fu
et al. (2016) included 62 eligible RCTs (N = 62,206) and also
found no significant difference in fracture risk over controls
(RR, 0.95; 95% CI, 0.83–1.10; P = 0.50). Of these two meta-
analyses the majority of studies were less than or equal to
52 weeks in duration.
Our findings are consistent with prior observational stud-
ies including Majumdar et al. [20] and Josse et al. [19] who
both found no increased risk of fractures associated with sita-
gliptin use, the latter including sitagliptin users and placebo
controls from the TECOS randomized clinical trial. Driessen
et al. conducted several observational studies [16–18], includ-
ing two cohort studies using the CPRD database comparing
DPP-4 inhibitor users to non-insulin anti-diabetic users
[16,18] neither of which observed an increased fracture risk
among DPP-4 users.
Our study contributes to the growing body of evidence
regarding the fracture risk of DPP-4 inhibitors. Specifically,
we include follow-up data until early 2016 and measure the
Fig. 1 – Flow diagram to identify new users of DPP-4 Inhibitors and Sulfonylureas.
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insulin, and thiazolidinediones. Previous observational stud-
ies primarily used a mixed antidiabetic comparator group;
where as we used a single class for each active comparator
to enhance the clarity of interpretation of our findings. It is
important to note that our comparator group also included
patients using other antidiabetic agents; however, all patients
in the reference group were continuously exposed to the com-
parator of interest. Specifically, we used sulfonylureas as the
referent group in the primary analysis, with other active com-
parators in secondary analyses. There has been speculation
that sulfonylureas may increase the risk of fragility fractures
due to the increased risk of hypoglycemia, although to our
knowledge this has not been previously demonstrated in
the literature [23–25]. We believe this makes sulfonylureas
an appropriate comparison group as they (as well as DPP-4
inhibitors) are commonly used as second line therapies.
Moreover, our study corroborates prior evidence demonstrat-
ing that thiazolidinediones increase fracture risk [6,7]. Specif-
ically, when we used thiazolidinediones as a comparator
group, we found a 53% lower fracture risk among DPP-4 users(i.e., an 113% increase risk of fracture among those who use
thiazolidinediones).
It is important to note that although we did not find an
association between DPP-4 inhibitor use and osteoporotic
fractures, there exists convincing mechanistic evidence sup-
porting the potential beneficial effects of incretin-based ther-
apies such as DPP-4 inhibitors on bone tissue. Indeed, the
incretin hormones GLP-1, GLP-2, and glucose-dependent
insulinotrophic polypeptide (GIP) have multiple actions on
bone. GLP-1 receptors are present on both osteoblasts and
osteocytes. In rodents, activation of GLP-1 receptors may
induce osteoblast differention leading to increased bone for-
mation [26], and decrease bone resportion via inhibition of
osteoclast activity [27]. GLP-2 receptor activiation may also
have a role in decreasing bone resportion and has been
shown to increase BMD in a dose-dependent manner [28].
GIP receptors are also present on osteoblasts, osteocytes,
and osteoclasts [29]. Notably, GIP receptor polymorphism
may result in differential fracture risk as was recently demon-
strated in a study of perimenopausal women with a func-
tional variant of the GIP receptor whom had a lower bone
Table 1 – Patient characteristics of new users of DPP-4 inhibitors and sulfonylureas.
DPP-4i SU
N 7993 26,636
Sociodemographic variables
Age (years) 57.1 (12.1) 59.3 (13.5)
Sex
Male 4767 (59.6%) 16,059 (60.3%)
Measure of deprivation
Least deprived 765 (9.6%) 2796 (10.5%)
Clinical variables
Diabetes duration (yrs) 2 (1.8) 1.1 (1.5)
Number of hospitalizations
0 7204 (90.1%) 22,398 (84.1%)
1 534 (6.7%) 2568 (9.6%)
2 147 (1.8%) 911 (3.4%)
3+ 108 (1.4%) 759 (2.8%)
Number of drugs
0–4 752 (9.4%) 3094 (11.6%)
5–10 3721 (46.6%) 11,610 (43.6%)
11+ 3520 (44%) 11,932 (44.8%)
HbA1c
<6.5% (<48 mmol/mol) 317 (4%) 1597 (6%)
6.5–7.5% (48–58 mmol/mol) 1439 (18%) 4039 (15.2%)
7.5–9% (58–75 mmol/mol) 3592 (44.9%) 8702 (32.7%)
9%+ (75 + mmol/mol) 2606 (32.6%) 11,913 (44.8%)
Unknown 39 (<1%) 385 (1.4%)
Heart Failure 78 (1%) 412 (1.5%)
Hypertension 1430 (17.9%) 5278 (19.8%)
Cirrhosis 12 (<1%) 93 (<1%)
Osteoporosis 48 (<1%) 256 (1%)
Dyslipidemia 291 (3.6%) 1301 (4.9%)
Ischemic heart disease 232 (2.9%) 1182 (4.4%)
Peripheral vascular disease 29 (<1%) 180 (<1%)
eGFR
<60 1072 (13.4%) 5027 (18.9%)
Anti-diabetic drug use
Metformin 7471 (93.5%) 20,723 (77.8%)
Acarbose 3 (<1%) 12 (<1%)
SGLT2 inhibitors 57 (<1%) 132 (<1%)
Meglitinide 64 (<1%) 50 (<1%)
Thiazolidinedione 349 (4.4%) 511 (1.9%)
Insulin 119 (1.5%) 386 (1.4%)
Other medication use
Oral contraceptions 170 (2.1%) 603 (2.3%)
Oral corticosteriods 2343 (29.3%) 8183 (30.7%)
Thiazide diuretics 1337 (16.7%) 4476 (16.8%)
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follow-up [29].
It is also plausible that a significant period of exposure is
required before any beneficial effects of DPP-4 inhibitors
would occur. Although there is some debate among experts
on the role that duration of diabetes plays on the overall risk
of fracture, with some claiming no association with duration
and some that short duration diabetes increases risk, the
majority of evidence appears to suggest that a long duration
of illness is a significant determinant of fracture risk [30–33].
Majumdar et al. (2016) conducted a large cohort study of
women (49,098 with and 8840 without diabetes) to assess
the impact of duration of type 2 diabetes on incident fracturesover 7 years [30]. They found that the risk for MOF only
increased after a long duration (>10 years), though the risk
of hip fracture was increased regardless of duration of illness.
Similarly, Swartz et al. reported an increase in hip fracture
rates after 14 years of diabetes duration compared to women
without diabetes [34]. This evidence highlights the fact that
the true impact of diabetes medications on MOF risk may
not be evident until longer term data is available.
4.1. Limitations
Despite the major strengths in this research, there are several
limitations. First, there is the potential for unmeasured con-
Table 2 – Incidence and Hazard ratios for fragility fracture in new users of DPP-4 inhibitors (DPP-4i) versus Sulfonylureas (A),
Insulin (B), and Thiazolidinediones (C).
(A) Primary analysis: comparison with new users of sulfonylureas (SU)
DPP-4i SU Total
N 7993 26,636 34,629
Person Year 9134 31,069 40,203
Events 27 162 189
Incidence rate per 1000 person years 3.0 (2–4.3) 5.2 (4.5–6.1) 4.7 (4.1–5.4)
Crude HR 0.57 (0.38–0.86) -ref- –
Adjusted HR 0.80 (0.51–1.24) -ref- –
(B) Seconary analysis: comparison with new users of insulin
DPP-4i Insulin Total
N 13,155 4559 17,714
Person Year 15,834 3078 18,912
Events 52 16 68
Incidence rate per 1000 person-years 3.3 (2.5–4.3) 5.2 (3.2–8.4) 3.6 (2.8–4.6)
Crude HR 0.71 (0.40–1.26) -ref- –
Adjusted HR 0.91 (0.40–2.09) -ref- –
(C) Secondary analysis: comparison with new users of thiazolidinediones (TZD)
DPP-4i TZD Total
N 12,694 3205 15,899
Person Year 15,014 4640 19,554
Events 51 26 77
Incidence per 1000 person-years 3.4 (2.6–4.5) 5.7 (3.9–8.4) 3.9 (3.2–4.9)
Crude HR 0.61 (0.38–0.99) -ref- –
Adjusted HR 0.47 (0.26–0.83) -ref- –
Fig. 2 – Hazard ratios and number of events within DPP4i and SU users across sensitivity analysis.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 3 6 ( 2 0 1 8 ) 1 5 9 –1 6 7 165founding; however, we were able to account for numerous
potential confounders in a clinically rich dataset using
advanced methods such as high-dimensional propensity
scores.
Second, though we were able to capture a mean follow-up
time 1.2 years and longer follow-up for a portion of patients
(11% of cohort had 3 or more years of follow-up and 3% of
cohort had 5 or more years follow-up), the impact of anti-diabetic agents on fracture risk may take much longer. As pre-
viously discussed, previous studies suggest that duration of
diabetes is a risk factor for increased fracture risk [30,32].
Therefore, further studies with longer follow-up periods are
required to rule out a protective effect of DPP-4 inhibitors
on fractures.
Third relates to potential outcome ascertainment bias.
There is a possibility that fractures were misclassified within
166 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 3 6 ( 2 0 1 8 ) 1 5 9 –1 6 7the CPRD and HES datasets; however, previous studies have
demonstrated that the CPRD data set to be highly valid
(>90%) for confirmed fractures, especially hip fracture diagno-
sis [35,36].
Fourth is the completeness of the data of risk factors for
fractures andmarkers of osteoporosis. There was limited data
on bone mineral density (only captured in <1% of our study
cohort) or bone turn over and no information on parental his-
tory of hip fracture or previous injurious falls. The impact of
the particular limitation is thought to be minimal given there
is no reason to anticipate that risk factors would be dis-
tributed differently across groups based on their prescriptions
for anti-diabetic drug treaments.
Finally, we have used prescription data as a proxy for
exposure to anti-diabetic agents. There is a risk that we
may have overestimated the exposure due to the occurrence
of primary and secondary non-adherence. It is possible that
some individuals may never fill a prescription written by their
provider (primary non-adherence), while others may fill a pre-
scription but never consume, or only partially consume the
medication (secondary non-adherence).
In conclusion, new DPP-4 inhibitors use was not associ-
ated with an increased risk of fractures among individuals
with type 2 diabetes when compared to sulfonylureas or insu-
lin; however these patients appeared to have a lower fracture
risk when compared to thiazolidinediones. Larger studies
with longer follow-up are needed to further characterize the
fracture risk among individual DPP-4 inhibitors and longer
term risks.
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